1. Home
  2. JBDI vs IMNN Comparison

JBDI vs IMNN Comparison

Compare JBDI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo JBDI Holdings Limited Ordinary Shares

JBDI

JBDI Holdings Limited Ordinary Shares

HOLD

Current Price

$1.04

Market Cap

13.7M

Sector

N/A

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$3.11

Market Cap

12.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JBDI
IMNN
Founded
1983
1982
Country
Singapore
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.7M
12.5M
IPO Year
2024
1985

Fundamental Metrics

Financial Performance
Metric
JBDI
IMNN
Price
$1.04
$3.11
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
1.1M
41.6K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,445,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$2.99
52 Week High
$3.00
$41.22

Technical Indicators

Market Signals
Indicator
JBDI
IMNN
Relative Strength Index (RSI) 68.64 32.98
Support Level $0.52 $3.28
Resistance Level $1.35 $3.89
Average True Range (ATR) 0.14 0.20
MACD 0.05 -0.04
Stochastic Oscillator 59.63 2.38

Price Performance

Historical Comparison
JBDI
IMNN

About JBDI JBDI Holdings Limited Ordinary Shares

JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. It's in the trading of reconditioned and recycling containers in Singapore and the Southeast Asia region. The company offers reconditioning and recycling drums, including open top drums, metal drums, plastic drums, plastic carboys, and intermediate bulk containers, as well as new drums, and collects waste drums and related products. It serves solvent, chemical, petroleum, and edible product oil industries.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: